contraindications to glp 1 agonists Exploring the Side Effects of GLP-1 Receptor Agonist: Ensure Its Optimal Positioning GI Adverse Effects of Glucagon-Like
Description
2023 2 Minute Medicine, Inc
The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031
Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence
22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.
These milestones will redefine how obesity care is delivered, marking a turning point that will shape the markets trajectory for 2026 and the years to come
GLP-1 Daily Support for Adult Healthy Lifestyles
